Letter

Postmarketing surveillance

BMJ 1994; 309 doi: 10.1136/bmj.309.6948.194a (Published 16 July 1994)
Cite this as: BMJ 1994;309:194.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. S Voss,
  2. F Harris
  1. Southampton and South West Hampshire Health Commission, Southampton SO16 4GX
  2. North and Mid Hampshire Health Commission, Basingstoke RG24 9NB.

    EDITOR, - The need to monitor the safety of medicines as they are used in clinical practice is well recognised and based on the Committee on the Safety of Medicines' yellow card system. Further evidence of drug safety is provided by the Drug Safety Research Unit's prescription event monitoring system1 and postmarketing surveillance performed by pharmaceutical companies or by …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular